Table 2.
Contemporary femoropopliteal nitinol stent studies
| Study name | Stent type | Number of patients | SFA, % | Popliteal, % | Claudicant, % | CLI, % | Mean lesion length, mm | Moderate or severe calcification, % | Occluded segment, % | Primary patency at 1 yr, % | Primary patency at 2 yr, % | Stent fracture at 1 yr, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DURABILITY I (2009)6 | Protégé EverFlex | 151 | – | – | 87 | 13 | 96 | 29 | 40 | 72 | – | 8 |
| RESILIENT (2010)16 | LifeStent | 134 | 95 | 5 | 100 | 0 | 71 | 35 | 26 | 81 | 0 | 3 |
| Dake et al (2011)17 | Zilver PTX | 236 | 95 | 8 | 91 | 9 | 63 | 57 | 25 | 83 | – | 0.9 |
| VIBRANT (2013)18 | VIABAHN | 72 | 100 | – | – | – | 190 | 62 | 61 | 50–60 | 40–50 | 2 |
| SUMMIT (2013)19 | EPIC | 100 | 92 | 9 | 94 | 6 | – | 48 | 29 | 85 | – | 0 |
| COMPLETE SE (2014)20 | COMPLETE SE | 196 | 96 | 4 | 98 | 2 | 61 | 91 | 30 | 73 | – | 0 |
Abbreviations: nitinol, nickel–titanium alloy; CLI, critical limb ischemia; yr, year; SFA, superficial femoral artery.